Healthcare: Air Liquide Continues Its Development with an Acquisition in the French Overseas Departments and Territories
09 July 2014 - 1:35AM
Business Wire
Regulatory News:
Increasing life expectancy and the rise in chronic diseases are
major public health issues. Air Liquide (Paris:AI)
is continuing to develop its home healthcare activity in
France with the acquisition of SEPRODOM, a key player in
home healthcare and monitoring of patients with chronic diseases in
the French overseas departments and territories.
Created in 2003, SEPRODOM has nearly 90 employees, caring for
4,500 patients at home in Reunion, Mayotte, Guadeloupe, and
New Caledonia.
SEPRODOM is recognised for the quality of its care
for patients that need respiratory assistance at home, in
particular oxygen therapy, mechanical ventilation and the treatment
of sleep apnea. SEPRODOM also cares for patients that require
treatment by infusion therapy and enteral nutrition
at home. And finally, it also supplies and distributes
medical equipment directly to patients' homes.
Air Liquide is favouring continuity for the company's
management with Jean-Philippe Rouquié, backed by the expertise
and commitment of his teams.
Pascal Vinet, Vice President, Healthcare Global
Operations and member of the Air Liquide group's Executive
Committee, commented: "This acquisition completes our service
offering in French overseas departments and territories. With the
integration of highly trained teams dedicated to patient care, our
home healthcare service offering in France will be
reinforced."
Air Liquide
Healthcare
supplies medical gases, home healthcare
services, hygiene products, medical equipment and specialty
ingredients.
In 2013, it served over 7,500
hospitals and more than 1 million patients at home
throughout the world.
The Group’s Healthcare business reached
€ 2,689 million in revenues in 2013, with the support
of its 12,000 employees.
The Home Healthcare
business
Air Liquide, European leader and
3rd worldwide in home healthcare, provides home
healthcare services in compliance with medical prescription for
patients suffering from chronic diseases such as COPD (Chronic
Obstructive Pulmonary Disease), sleep apnea and diabetes. These
home healthcare services are being developed in addition to
hospital care, enabling patients to enjoy better quality of life
and local authorities to reduce costs. Home healthcare represents
48% of Air Liquide's revenue in Healthcare in 2013.
World leader in gases, technologies and services for Industry
and Health, Air Liquide is present in 80 countries with more than
50,000 employees and serves more than 2 million customers and
patients. Oxygen, nitrogen and hydrogen have been at the core of
the Group’s activities since its creation in 1902. Air Liquide’s
ambition is to be the leader in its industry, delivering long-term
performance and acting responsibly.
Air Liquide ideas create value over the long term. At the core
of the company’s development are the commitment and constant
inventiveness of its people.
Air Liquide anticipates the challenges of its markets, invests
locally and globally, and delivers high-quality solutions to its
customers and patients, and the scientific community.
The company relies on competitiveness in its operations,
targeted investments in growing markets and innovation to deliver
profitable growth over the long-term.
Air Liquide’s revenues amounted to € 15.2 billion in 2013, and
its solutions that protect life and the environment represented
around 40% of sales. Air Liquide is listed on the Paris Euronext
stock exchange (compartment A) and is a member of the CAC 40 and
Dow Jones Euro Stoxx 50 indexes.
www.airliquide.comFollow us on Twitter
@AirLiquideGroup
Air LiquideCorporate CommunicationsGarance
Bertrand, + 33 (0)1 40 62 59 62Anne Michaud, + 33 (0)1 40 62 50
59orInvestor RelationsVirginia Jeanson, +33 (0)1 40 62 57
37Annie Fournier, +33 (0)1 40 62 57 18orAir Liquide Healthcare
CommunicationMuriel Doucet, + 33 (0)1 49 69 46 46
C3 AI (NYSE:AI)
Historical Stock Chart
From Aug 2024 to Sep 2024
C3 AI (NYSE:AI)
Historical Stock Chart
From Sep 2023 to Sep 2024